Joint IFPMA – EFPIA – EUCOPE statement to support the adoption of the WHA Resolution on Rare Diseases

On 5 May 2025, IFPMA, EFPIA, and EUCOPE issued a statement supporting the World Health Assembly Resolution and Global Action Plan on Rare Diseases, in line with a call to action by a coalition of civil society organizations.

UN Multi-stakeholder Hearing on the Prevention and Control of Noncommunicable Diseases (NCDs) and the Promotion of Mental Health and Well-being

On 2 May 2025 in New York, IFPMA delivered a statement at the UN Multi-stakeholder Hearing on the Prevention and Control of Noncommunicable Diseases (NCDs) and the Promotion of Mental Health and Well-being.

Open letter from the innovative pharmaceutical industry to G20 Ministers in support of the G20 Health Agenda

On 17 April 2025, IFPMA and IPASA submitted an open letter to G20 Ministers in support of the advancement of the G20 Health Agenda.

Conclusion of the 13th resumed meeting of the Intergovernmental Negotiating Body (INB) for a WHO instrument on pandemic prevention, preparedness, and response

On the conclusion of the 13th resumed meeting of the Intergovernmental Negotiating Body in Geneva, IFPMA delivered a statement.

13th Resumed meeting of the Intergovernmental Negotiating Body (INB)

On 7 April in Geneva, IFPMA delivered a statement at the 13th resumed meeting of the INB to agree a WHO instrument for pandemic prevention, preparedness, and response.

Biopharmaceutical CEO Roundtable gathers in London, focusing on global health challenges and role of pharmaceutical innovation

Pharmaceutical industry issues call for collective action to address the rising global burden of chronic disease

Statement delivered at the 13th Intergovernmental Negotiating Body (INB 13)

On 17 February 2025, IFPMA delivered a statement during the 13th Intergovernmental Negotiating Body (INB 13).

156th WHO Executive Board (EB156): Constituency statement on climate change and health

On 8 February 2025 at the EB156 in Geneva, the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), Global Diagnostic Imaging, Healthcare IT & Radiation Therapy Trade Association (DITTA), Global Self-Care Federation (GSCF), and International Hospital Federation (IHF) delivered a statement on Agenda Item 22: Climate change and health.  

156th WHO Executive Board (EB156): Fight the Fakes Alliance statement on substandard and falsified products

On 7 February 2025 at the EB156 in Geneva, the Fight the Fakes Alliance delivered a statement on substandard and falsified medical products. IFPMA is a member of Fight the Fakes Alliance.

156th WHO Executive Board (EB156): Constituency statement on health emergencies

On 6 February at the EB156, the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), Global Diagnostic Imaging, Healthcare IT & Radiation Therapy Trade Association (DITTA), Global Self-Care Federation (GSCF), International Pharmaceutical Federation (FIP), International Alliance of Patients’ Organizations (IAPO), and International Generic and Biosimilar Medicines Association (IGBA) delivered a statement on Agenda Item 15: WHO’s work in health emergencies. 

156th WHO Executive Board (EB156): Individual statement on non-communicable diseases

On 5 February at the EB156 in Geneva, IFPMA delivered a statement on non-communicable diseases (NCDs).